COMMUNIQUÉS West-GlobeNewswire

The Real Ironman Economy: How AI, Superfibers, and Defense Tech Could Theoretically Converge
02/02/2026
DENVER, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Recent reports that Palantir Technologies (NASDAQ: PLTR) has been tapped by President Trump to deploy AI systems to hunt fraud, likened in headlines to an AI “Ironman suit”, [...]
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
02/02/2026
Industry’s Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications MARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today [...]
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
02/02/2026
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute [...]
Targeted Genomics Launches Celiac Genetic Testing Services for Texas Physicians
02/02/2026
Partnering with Texas pathology group enables a genetics-focused strategy to address the hidden epidemic of celiac disease IRVINE, Calif. and SAN ANTONIO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Targeted Genomics LLC , [...]
Nova Leap Health Corp. Launches Palliative Care Division In Nova Scotia Through Earth Angels Home Care
02/02/2026
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Feb. 02, 2026 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
02/02/2026
Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation Techniques HOUSTON, TX, Feb. 02, 2026 (GLOBE [...]
Quotient Therapeutics Appoints Seasoned Life Sciences Executive, Susan Keefe, as Chief Financial Officer
02/02/2026
CAMBRIDGE, Mass. and CAMBRIDGE, United Kingdom, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has appointed [...]
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
02/02/2026
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million upfront payment [...]
Johns Hopkins Health Plans Executive Elected Chair of Medicare Advantage Plan Alliance Compliance Forum
02/02/2026
Melissa Mohon to Lead National Organization Dedicated to Improving Regulatory Compliance and Quality Care for Medicare Beneficiaries HANOVER, Md., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Melissa L. Mohon, Executive Director [...]
Iridex Announces Plans to Relocate Headquarters
02/02/2026
Move expected to generate significant cost savings MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical [...]
MAPS and Columbia University Partner on First-of-its-Kind Study of MDMA-Assisted Couples Therapy
02/02/2026
Anonymous survey with optional confidential interviews will document how practitioners facilitate MDMA-assisted couples therapy Findings to inform ethical guidelines, future clinical trial protocols, and policy [...]
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
02/02/2026
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding [...]
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
02/02/2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: [...]
ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan
02/02/2026
For the treatment of aggression and social withdrawal MADRID and CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a [...]
BrainCo’s Brain-Computer Interface Headband Supporting Social Skills Development in Children with Autism
02/02/2026
Somerville, MA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Improving social communication skills in children with autism has traditionally relied on structured teaching approaches and stable support environments. With the [...]
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
02/02/2026
Product is currently under review with the FDA Potential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative [...]
CROSSJECT annonce l’initiation de couverture de son titre par Portzamparc (Groupe BNP Paribas)
02/02/2026
CROSSJECT annonce l’initiation de couverture de son titre par Portzamparc (Groupe BNP Paribas) DIJON, France - 02 février 2026 (07h15CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), la société pharmaceutique de [...]
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
02/02/2026
Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful efficacy in patients [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
02/02/2026
COPENHAGEN, Denmark, February 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount [...]

Pages